Molecule · Mechanism

How Does R 1,3 Butanediol Become BHB?

You drink an alcohol precursor. After liver conversion, blood BHB rises and the meter detects the ketone body D-BHB. Two liver enzymes do the work. Here is the pathway step by step, what has been measured in people, and what the pathway does — and does not — tell you.

See the pathway Compare it with the ketone ester
Short answer

Short answer

R 1,3 butanediol is a precursor, not BHB in the bottle. After absorption, it is metabolized primarily in the liver: alcohol dehydrogenase converts it to an aldehyde intermediate, and aldehyde dehydrogenase converts that intermediate to D-BHB. Human oral studies confirm that free R 1,3 butanediol raises circulating BHB; the enzyme-by-enzyme pathway is supported by mechanistic liver-fraction work.

“Raises BHB” is a pharmacokinetic result. It does not by itself establish performance, cognition, recovery or another outcome. This page explains the conversion; the pages linked alongside hold the comparisons and the evidence rules.

The pathway

Two enzyme steps, one intermediate.

The route below is the one described in mechanistic work on human and rat liver fractions and in the human kinetics literature on the ketone ester, whose released butanediol follows the same steps.

Canonical pathway · hepatic Precursor · an alcohol R 1,3 butanediol (R)-butane-1,3-diol · not a ketone body alcohol dehydrogenase Intermediate · an aldehyde (R)-3-hydroxybutyraldehyde also written (R)-3-hydroxybutanal or the (R)-aldol aldehyde dehydrogenase Product · the ketone body D-BHB (R-BHB) the same circulating ketone body a meter reads liver

Mechanistic liver-fraction evidence, not a human performance trial. The enzyme assignment and the identity of the intermediate come from Panse & Gerk 2025 (pooled human and rat liver fractions); the human description of the same conversion for the ester's released butanediol comes from Clarke 2012 and Soto-Mota 2020.

Step by step

What each step means.

1 Absorption of an alcohol. What is drunk is R 1,3 butanediol — a four-carbon alcohol with two hydroxyl groups. R 1,3 butanediol itself is not a ketone body; before metabolism, it is the alcohol precursor being administered, and calling it “BHB” at this point is a category error. It is absorbed as itself and carried to the liver. A precursor, by definition.
2 Alcohol dehydrogenase: alcohol → aldehyde. The first enzyme oxidises one hydroxyl group, producing (R)-3-hydroxybutyraldehyde — the intermediate the liver-fraction work identifies directly, also written (R)-3-hydroxybutanal or the (R)-aldol. In pooled human liver fractions, R 1,3 butanediol metabolism showed saturable kinetics as substrate concentration increased. That is an in-vitro mechanistic observation, not a human dose-response recommendation. Panse & Gerk 2025 · liver fractions
3 Aldehyde dehydrogenase: aldehyde → D-BHB. The second enzyme oxidises the aldehyde to the acid — D-BHB, the R-isomer, the same ketone body the body makes during fasting and the one a blood meter reports. Once formed, D-BHB is the same chemical species regardless of whether it arose endogenously or from metabolism of an exogenous precursor. That chemical identity does not make the starting products or their trial evidence interchangeable. Same product; different starting point.

Stereochemistry: preclinical liver work indicates the R stereoisomer is converted to physiological ketone bodies more readily than the S stereoisomer. Racemic (R,S) products contain both. That finding is from perfused rat liver, not a human head-to-head — it is noted here as mechanism, not as a human outcome.

In people

What happens after drinking free R 1,3 butanediol.

Two human kinetics datasets, each attached to its own dose and protocol. Neither is a target. Neither study tested a performance, cognition, recovery or other efficacy endpoint; they are used here for ketone-delivery kinetics.

≈ 1.2 mMpeak, about 40 minutes after a single 10 g dose

In a double-blind crossover, twelve healthy fasted adults took 10 g of (R)-1,3-butanediol as one of three formulations tested on separate days. The blood BHB rise above baseline was about +0.8 mM* — roughly half the rise from 10 g of the Veech Ketone Ester in the same people.

Falkenhain et al. · J Diet Suppl 2024 · peak and timing as reported in Lowder et al. 2023
2.10 ± 0.97 mMmean peak, about 2¼ hours after the first of three 11.5 g servings

In an open-label, uncontrolled study funded by the ingredient's manufacturer, 26 healthy adults drank 34.5 g of (R)-1,3-butanediol in three servings over an hour, fasted. Individual peaks ranged from 1.0 to 5.5 mM; the mean was still about 1.1 mM five hours after the first serving. Most reported no or mild symptoms.

Lowder et al. · Front Physiol 2023 · kinetics and tolerability only

* Approximate rise above baseline calculated from the published baseline and peak values, not a treatment-effect figure quoted verbatim from the paper. A twelve-person pharmacokinetic pilot; it measured BHB exposure, not performance or cognition. Both studies confirm the pathway's end result in people — circulating BHB rises — and nothing beyond it.

The ester connection

Where the Veech Ketone Ester overlaps this pathway — and where it does not.

Where it overlaps

  • The ester releases R 1,3 butanediol. The Veech Ketone Ester is one bonded molecule. After hydrolysis it releases one D-BHB molecule directly and one R 1,3 butanediol molecule.
  • The released diol follows this pathway. Alcohol dehydrogenase, the aldehyde intermediate, aldehyde dehydrogenase, D-BHB — the same hepatic conversion described for the free diol.
  • Intact ester was not detected in plasma. In the Clarke 2012 human kinetics study, intact ester was not detected in plasma; the measured circulating products reflected rapid hydrolysis and downstream metabolism.

Where it does not

  • Different administered molecule. One is an ester; the other is an alcohol. What was dosed in every ester trial was the intact ester.
  • VKE hydrolysis releases D-BHB directly. After VKE is hydrolyzed, one product is already D-BHB. Hydrolysis also releases R 1,3 butanediol, which still follows the hepatic conversion pathway shown on this page. Free R 1,3 butanediol does not provide that directly released D-BHB component.
  • Different kinetics at matched dose. Same 10 g, same people: roughly twice the BHB rise from the ester. The shared pathway does not make the curves the same.
  • Separate evidence bases. Shared downstream pathway ≠ same administered molecule ≠ same pharmacokinetics ≠ same outcome evidence. The ester's trials describe the ester; the free diol's trials describe the free diol.

The side-by-side kinetics table lives on the metabolism comparison; the evidence-transfer argument lives on its own page. This page does not repeat either.

Limits

What the pathway does not prove.

1That any outcome follows.A conversion route explains how BHB appears. It says nothing about performance, cognition, recovery or hunger — each of those has its own instrument and needs its own trial on the free diol.
2That ester results transfer to the free diol — or the reverse.Sharing a downstream step is not sharing a trial. The ester's positive, mixed and negative human results describe the intact ester; the free diol's trials describe the free diol.
3That one route is “good” and the other “bad.”Direct release and hepatic conversion are two ways BHB arrives. The defensible distinctions are exact molecule, bond, pharmacokinetics, dose and outcome evidence — not a verdict on the pathway.
Scope

This page explains one conversion in the liver. It is not an efficacy claim for any product.

It also does not explain effects other than ketone delivery that have been reported with free 1,3-butanediol in some human studies; those mechanisms are not established in the sources indexed here.

Becomes BHB is a pathway. Is BHB is a molecule. The research follows the molecule that was administered.

The product-match test
From evidence to the bottle

Becoming BHB does not make it VKE.

Free R 1,3 Butanediol is a precursor. KetoneAid uses intact Veech Ketone Ester, a different administered molecule with different pharmacokinetics and its own human outcome evidence.

If the question is which product matches a VKE study, the answer starts with what is in the bottle — not just what eventually appears on the meter.

Shop KetoneAid Compare VKE vs R 1,3 Butanediol
Go deeper

From the pathway to the evidence.

The comparison

Ketone ester vs R 1,3 butanediol

Molecule, kinetics, dose and evidence side by side, with the matched-dose head-to-head.

See the metabolism  The transfer question

Can ester research apply to R 1,3 butanediol?

Five things “the same” can mean — and the one that holds.

Read the answer  The category

Exogenous ketones

Ketone ester, R 1,3 butanediol, BHB salts and D-BHB free acid — every type, what it is and what it has shown.

Compare the types  The ketone body

What is BHB?

The molecule at the end of the pathway — D- versus L-, and how it is measured.

Start with BHB 
Back to Ketone Science Explore Veech Ketone Ester science
References cited on this page
  1. Panse N, Gerk PM. Characterizing the Hepatic Metabolic Pathway of Ketone Ester and Subsequent Metabolites Using Human and Rat Liver Fractions. AAPS J. 2025;27(2):65. PubMed ↗Mechanistic liver-fraction study (pooled human and rat), not a clinical trial. Source for the enzyme assignments, the identity of the intermediate — (R)-aldol / (R)-3-hydroxybutanal / (R)-3-hydroxybutyraldehyde — and the saturable-metabolism observation. Authors declare no conflict of interest.
  2. Clarke K, Tchabanenko K, Pawlosky R, et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012;63(3):401–408. PubMed ↗Human kinetics of the ester; intact ester not detected in plasma; describes hepatic conversion of the released R 1,3 butanediol.
  3. Soto-Mota A, Norwitz NG, Clarke K. Why a d-β-hydroxybutyrate monoester? Biochem Soc Trans. 2020;48(1):51–59. PubMed ↗Review: the monoester bond is cleaved, yielding BHB and butanediol; the latter is taken up by the liver and converted to BHB.
  4. Lowder J, Fallah S, Venditti C, Musa-Veloso K, Kotlov V. An open-label, acute clinical trial in adults to assess ketone levels, gastrointestinal tolerability, and sleepiness following consumption of (R)-1,3-butanediol. Front Physiol. 2023;14:1195702. PubMed ↗Open-label, uncontrolled, n = 26; manufacturer-funded, funder involved in design. Kinetics and tolerability only.
  5. Falkenhain K, Daraei A, Little JP. The Effect of Novel Exogenous Ketone Supplements on Blood Beta-Hydroxybutyrate and Glucose. J Diet Suppl. 2024;21(1):38–52. PubMed ↗Matched 10 g crossover; rise-above-baseline figure is a calculation from the published values. The (R)-1,3-butanediol peak (1.2 ± 0.3 mM at ~40 min) is as reported by Lowder et al. 2023.
  6. Desrochers S, David F, Garneau M, Jetté M, Brunengraber H. Metabolism of R- and S-1,3-butanediol in perfused livers from meal-fed and starved rats. Biochem J. 1992;285:647–653. DOI ↗Preclinical (perfused rat liver): source for the R- vs S-isomer conversion point only.